Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS

Azitra, Inc. AZTR

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-11.0M
$-11.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -11.0
-5M-10M
20222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -1086.1%
-1000%-2000%-3000%
202220232025
ROE
FY2025 · ROE -230.7%
-100%-200%
202220232025
Three returns, three denominators.

Each USD of equity lost 231 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -11.2
-5M-10M
202220232025

Total assetsUSD 5.0M
EquityUSD 3.8M
CashUSD 2.1M
Current ratio2.83×

Equity funds 76% of total assets.

The 4-year record

4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
AZTR, 4-year financial record
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0
Income tax $B0.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0
EPS, diluted $−2.25−15.70−54.98−12.74
Dividend / sh $◌◌◌◌
Payout % — not applicable: no dividend————
ROE %−230.7−208.3——
Shares out B0.010.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 16 reconciliationsAUDITED

Reconciled in 4 of the 4 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 15 checks were skipped: EPS is not tagged before 2022.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image